- Investing.com
Metrics to compare | NBTX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNBTXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −80.5x | −3.0x | −0.3x | |
PEG Ratio | −1.21 | −0.01 | 0.00 | |
Price / Book | −22.8x | 0.9x | 2.6x | |
Price / LTM Sales | 59.2x | 17.9x | 3.1x | |
Upside (Analyst Target) | −17.0% | 187.5% | 47.6% | |
Fair Value Upside | Unlock | 7.4% | 5.6% | Unlock |
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.